In our study, we confirmed in vitro findings of TYRO3 and AXL upregulation and MAPK pathway activation upon prolonged PI3Kα inhibition in a panel of 5 unique HNSCC PDX models treated for up to 100 days with alpelisib. This evidence concerns the gene AXL and head and neck squamous cell carcinoma.